ID.1
Item
patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis.
boolean
C0001418 (UMLS CUI [1,1])
C0034896 (UMLS CUI [1,2])
C0001418 (UMLS CUI [1,3])
C0009368 (UMLS CUI [1,4])
C0019638 (UMLS CUI [1,5])
C0027627 (UMLS CUI [2])
ID.2
Item
patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. patients must not have been previously treated with the combination of irinotecan/5-fu/lv.
boolean
C0392920 (UMLS CUI [1])
C0123931 (UMLS CUI [2,1])
C0016360 (UMLS CUI [2,2])
C0023413 (UMLS CUI [2,3])
ID.3
Item
patients must be past their 18th birthday at the time of enrollment.
boolean
C0001779 (UMLS CUI [1])
ID.4
Item
patients must have a performance status of 0-2 at the time of registration.
boolean
C1520224 (UMLS CUI [1])
ID.5
Item
patients must have a life expectancy of > 3 months.
boolean
C0023671 (UMLS CUI [1])
ID.6
Item
if patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment.
boolean
C2004454 (UMLS CUI [1])
ID.7
Item
patients must have a pretreatment leukocyte count > 3,000/l, absolute neutrophil count >1500/l, hemoglobin >8 mg/dl, and platelet count of > 150,000/l within 2 weeks of enrollment.
boolean
C0023508 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
ID.8
Item
patients must have adequate renal function, as documented by a serum creatinine < 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin < 1.1 mg/dl within 2 weeks of enrollment.
boolean
C1278039 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
ID.9
Item
patients must not have active infection.
boolean
C0009450 (UMLS CUI [1])
ID.10
Item
patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent.
boolean
C0009488 (UMLS CUI [1])
ID.11
Item
patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment.
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
ID.12
Item
pregnant or lactating women may not participate. women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. men and women of reproductive potential must use an effective contraceptive method during the study.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0015895 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
ID.13
Item
there must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol.
boolean
C1707479 (UMLS CUI [1])
ID.14
Item
all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
boolean
C0021430 (UMLS CUI [1])